T1237 Predictors of Ulcerative Colitis (UC) Relapse From a Large 12 Month Prospective Mesalamine Study von Korzenik, Joshua R, Kane, Sunanda V, Lashner, Bret, Leighton, Jonathan A, Mahadevan, Uma, Marion, James F, Safdi, Michael, Ramsey, Charles A. Sninsky David, Wang, Jun, Sandborn, William J

Volltext

Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis von Sandborn, William J, Korzenik, Joshua, Lashner, Bret, Leighton, Jonathan A, Mahadevan, Uma, Marion, James F, Safdi, Michael, Sninsky, Charles A, Patel, Raman M, Friedenberg, Keith A, Dunnmon, Preston, Ramsey, David, Kane, Sunanda

Volltext

W1167 Patient's Functional Assessment (PFA) Provides Insight Into the Patient's Perception for Onset of Action Using Delayed-Release Mesalamine for Ulcerative Colitis (UC) von Sninsky, Charles A, Ramsey, David

Volltext

Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection von Li, Yonghong, Chang, Monica, Abar, Olivia, Garcia, Veronica, Rowland, Charles, Catanese, Joseph, Ross, David, Broder, Samuel, Shiffman, Mitchell, Cheung, Ramsey, Wright, Teresa, Friedman, Scott L, Sninsky, John

Volltext

M1235 Different Simple Clinical Colitis Activity Index (SCCAI) Cut-off Points Used to Define Remission of Ulcerative Colitis (UC) in Large Mesalamine Study von Leighton, Jonathan A, Kane, Sunanda V, Korzenik, Joshua R, Lashner, Bret, Mahadevan, Uma, Marion, James F, Safdi, Michael, Sninsky, Charles A, Ramsey, David, Wang, Jun, Sandborn, William J

Volltext